Home
/
IONIS PHARMACEUTICALS INC
/
Financials
/
Quarterly
IONIS PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that IONIS PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$120.91M
Nov 7, 2017
Q2
2017
Jun 30, 2017
$104.15M
Aug 9, 2017
Q1
2017
Mar 31, 2017
$110.30M
May 9, 2017
Q3
2017
Sep 30, 2016
$110.93M
Nov 7, 2017
Q2
2017
Jun 30, 2016
$38.47M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$36.87M
May 9, 2017
Q3
2016
Sep 30, 2015
$49.12M
Nov 9, 2016
Q2
2016
Jun 30, 2015
$120.43M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$62.58M
May 5, 2016
Q3
2015
Sep 30, 2014
$44.06M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$57.08M
Aug 5, 2015
Q1
2015
Mar 31, 2014
$28.16M
May 5, 2015
Q3
2014
Sep 30, 2013
$23.59M
Nov 7, 2014
Q2
2014
Jun 30, 2013
$38.09M
Aug 4, 2014
Q1
2014
Mar 31, 2013
$43.36M
May 6, 2014
Q3
2013
Sep 30, 2012
$11.60M
Nov 5, 2013
Q2
2013
Jun 30, 2012
$47.34M
Aug 6, 2013
Q1
2013
Mar 31, 2012
$23.24M
May 7, 2013
Q3
2012
Sep 30, 2011
$20.71M
Nov 6, 2012
Q2
2012
Jun 30, 2011
$24.82M
Aug 6, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$156.72M
Oct 29, 2025
Q2
2025
Jun 30, 2025
$452.05M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$131.61M
Apr 30, 2025
Q3
2025
Sep 30, 2024
$133.81M
Oct 29, 2025
Q2
2025
Jun 30, 2024
$225.25M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$119.50M
Apr 30, 2025
Q3
2024
Sep 30, 2023
$144.21M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$188.41M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$130.52M
May 7, 2024
Q3
2023
Sep 30, 2022
$159.77M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$133.79M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$141.92M
May 3, 2023
Q3
2022
Sep 30, 2021
$133.09M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$125.75M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$111.61M
May 4, 2022
Q3
2021
Sep 30, 2020
$160.08M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$145.54M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$133.37M
May 5, 2021
Q3
2020
Sep 30, 2019
$167.89M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$163.81M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($128.61M)
Oct 29, 2025
Q2
2025
Jun 30, 2025
$123.55M
Jul 30, 2025
Q1
2025
Mar 31, 2025
($146.94M)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($140.48M)
Oct 29, 2025
Q2
2025
Jun 30, 2024
($66.27M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($142.80M)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($147.41M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($85.29M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($124.32M)
May 7, 2024
Q3
2023
Sep 30, 2022
($46.99M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($105.14M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($65.17M)
May 3, 2023
Q3
2022
Sep 30, 2021
($82.47M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($80.88M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($89.87M)
May 4, 2022
Q3
2021
Sep 30, 2020
($24.47M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($25.64M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($39.63M)
May 5, 2021
Q3
2020
Sep 30, 2019
$26.16M
Nov 4, 2020
Q2
2020
Jun 30, 2019
($876.0K)
Aug 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($160.18M)
Oct 29, 2025
Q2
2025
Jun 30, 2025
$139.82M
Jul 30, 2025
Q1
2025
Mar 31, 2025
($146.86M)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($148.66M)
Oct 29, 2025
Q2
2025
Jun 30, 2024
($66.09M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($149.51M)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($143.27M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($90.20M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($114.15M)
May 7, 2024
Q3
2023
Sep 30, 2022
($59.15M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($85.51M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($57.50M)
May 3, 2023
Q3
2022
Sep 30, 2021
($85.85M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($72.97M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($91.97M)
May 4, 2022
Q3
2021
Sep 30, 2020
($36.54M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($51.75M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($61.13M)
May 5, 2021
Q3
2020
Sep 30, 2019
$2.52M
Nov 4, 2020
Q2
2020
Jun 30, 2019
($18.83M)
Aug 5, 2020